Fujifilm Diosynth to create biocampus in the UK

By Vassia Barba

- Last updated on GMT

(Image: Getty/champc)
(Image: Getty/champc)

Related tags Fujifilm diosynth biotechnologies Fujifilm facility

Fujifilm Diosynth announced plans to build a research center in the UK to answer growing demand in services for biologics, vaccines, and gene therapies development.

Located in Billingham, UK, the research center, known as BioCampus, will include a 42,000-square-foot office space, which is expected to house approximately 250 of the company’s existing employees, with an additional 50 people to be hired.

The site will have the potential to be expanded in the future with additional R&D laboratories or manufacturing facilities.

The project will see Fujifilm Diosynth Biotechnologies invest up to £14.5m ($17.11m), utilizing funding by the Tees Valley Mayor and Combined Authority, as well as from the UK government’s Local Growth Fund.

By building the new facility, Fujifilm Diosynth expects to meet the growing demand for its portfolio of partner programs, including development and manufacturing services of biologics, vaccines and gene therapies, the company stated.

Paul Found, the company’s chief operating officer, stated that the BioCampus will enable Fujifilm Diosynth to significantly enhance the quality of the working environment for its employees.

Construction of the BioCampus is expected to be completed by March 2021.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars